Compugen (CGEN) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Compugen (CGEN) has outperformed Protara Therapeutics (TARA) over the past year, gaining 17.1% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -66.7% for CGEN. Compugen is the larger company by market cap ($200.8 million vs $156.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | TARA |
|---|---|---|
| Share price | $2.12 | $2.65 |
| Market cap | $200.82M | $156.60M |
| 1-day change | -1.40% | +2.32% |
| YTD return | +38.56% | -50.28% |
| 1-year return | +17.13% | -47.73% |
| 5-year return | -66.67% | -61.26% |
| P/E ratio (TTM) | 5.58 | — |
| EPS (TTM) | $0.38 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $7.82 |
| 52-week low | $1.43 | $2.51 |
| Distance from 52-week high | -34.57% | -66.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.98% | +870.19% |
| Average volume | 244.17K | 804.10K |
| Shares outstanding | 94.72M | 59.10M |
| Employees | 75 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed TARA by 64.9 percentage points over the past year.
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CGEN vs TARA FAQ
Which is bigger, Compugen or Protara Therapeutics?
Compugen (CGEN) is larger, with a market capitalization of $200.82M compared with $156.60M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, CGEN or TARA?
CGEN returned +17.13% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.